Biotecnica develops peptones ‘significantly less costly’ than ultrafiltered equivalents
EndoLow Peptones are ‘next generation’ – they were developed to meet the needs of the biopharma industry in terms of the production of medications, vaccines and diagnostic products, said the Oaxaca, Mexico-based firm, a supplier of biological raw materials for production of culture media.
When asked what makes these peptones high-performing, Robert Gallo, president, Global BioIngredients, Biotecnica’s partner in the US and Canada, told us:
“EndoLow Peptones represent a new generation of peptone because they have low levels of endotoxins without requiring ultrafiltration, maintaining growth factors and other biomolecules of interest. These biomolecules improve cell density and the production of recombinant proteins in cell cultures and microbiological fermentation processes.”
Retention of growth factors and other biomolecules
The traditional process of ultrafiltration effectively removes endotoxins, but it also has the adverse effect of removing larger digestion products – peptides – and growth factors greater than 10kd, essential for optimal cell growth, he said.
“As a result of our proprietary Low Endotoxin Count (LEC) process, we can reduce endotoxins below ultrafiltered standards without removing the larger biomolecules at a fraction of the cost of ultrafiltered alternatives,” continued Gallo.
Biotecnica also confirmed that a LAL test for endotoxin level is conducted on the peptones to ensure levels are below 200 EU/gr.
Studies conducted by its R&D department, it added, show cells grown in media containing the new peptones achieve greater cell density when compared to media prepared with ultrafiltered versions.
The range currently includes three types of peptones: EndoLow Casein Peptone, EndoLow Meat Peptone (Bovine) and EndoLow Soy Peptone, which is developed with raw materials certified as non-GMO and animal-free.
“Peptones such as Casien Peptone, that do not have commercially available ultrafiltered equivalents, may still be a candidate for our LEC process making low endotoxin options available where none had existed previously,” noted Gallo.
